The Multicenter International (U.S., Japan, Canada) LAM Efficacy and Safety of Sirolimus (MILES) trial demonstrated that sirolimus, an mTOR inhibitor, stabilized lung function and improved functional performance and quality of life in patients with LAM [8]. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.